Twist Bioscience Corp (NASDAQ: TWST)

Twist Bioscience Corporation develops a proprietary DNA synthesis platform that enables the production of synthetic genes oligonucleotides and related biologics for research and industrial applications. The company miniaturizes chemical DNA synthesis reactions onto a silicon chip allowing the parallel manufacture of up to one million oligonucleotides per chip. This technology reduces reagent consumption and cost while increasing speed and scalability compared with traditional plate based methods. Twist Bioscience serves markets in health care chemicals materials food agriculture and academic research by providing products that support drug discovery enzyme engineering crop improvement and basic biological investigation.

The company generates revenue primarily from the sale of synthetic biology products next generation sequencing tools and biopharma services. Synthetic biology revenue comes from clonal and non clonal genes gene fragments oligonucleotide pools and immunoglobulin G protein products. Next generation sequencing revenue is derived from target enrichment probes library preparation kits synthetic controls and related workflow solutions. Biopharma services revenue is earned through antibody discovery partnership programs library generation screening developability assays and antibody expression and characterization activities. In fiscal year 2025 the company served more than 3 800 customers and reported total revenue of 376.6 million dollars. Revenue by sector included 215.1 million dollars from health care 93.2 million dollars from chemicals materials 65.9 million dollars from academic research and 2.4 million dollars from food agriculture.

The company operates through the following segments Synthetic Biology Next Generation Sequencing Tools and Biopharma Services.

• The Synthetic Biology segment designs manufactures and sells clonal genes non clonal genes gene fragments oligonucleotide pools and immunoglobulin G proteins. Products are delivered through standard and express timelines with the express option providing delivery within five business days at a premium price. The segment serves biotech pharma industrial chemical agricultural companies and academic laboratories for applications such as drug discovery enzyme engineering crop trait improvement and basic research.

• The Next Generation Sequencing Tools segment produces target enrichment probes library preparation kits synthetic controls and RNA sequencing workflows. These products improve sequencing accuracy lower downstream costs and enable rapid sample to sequencer workflows for applications such as liquid biopsy minimal residual disease and cancer diagnostics. Customers include diagnostic companies hospitals research institutions agricultural biotech firms and consumer genetics companies.

• The Biopharma Services segment provides antibody discovery and optimization services under partnership agreements with pharmaceutical and biotechnology companies. Services encompass library generation high throughput screening developability assays antibody expression and characterization and lead selection. Revenue is generated via licensing fees fee for service arrangements and success based milestones tied to clinical regulatory and commercial outcomes.

Twist Bioscience holds a strong position in the synthetic biology market due to its silicon based DNA synthesis platform that delivers high throughput low cost and rapid turnaround. The company competes with established nucleic acid providers such as GenScript Integrated DNA Technologies Thermo Fisher Scientific and Eurofins Genomics as well as newer entrants like Ansa Biotechnologies and Telesis Bio. In the next generation sequencing space Twist faces competition from Illumina Roche Agilent and other suppliers of library preparation and target enrichment products. Its competitive advantages include proprietary silicon chip technology a fully integrated software and automation platform and a broad product portfolio that spans genes oligonucleotides proteins and antibody services. The company’s ability to scale production while maintaining low error rates and short lead times enables it to win market share from legacy providers that rely on multi well plate processes.

Twist Bioscience serves a global customer base of more than 3 800 organizations spanning health care chemicals materials food agriculture and academic research. Specific partners include Bayer Boehringer Ingelheim GmbH Takeda Pharmaceutical Company Limited Adicet Bio Ono Pharmaceutical Ltd Kyowa Kirin Invetx Inc Astellas Pharma Inc and Neogene Therapeutics Inc. The company also works with academic laboratories government agencies and contract research organizations that use its products for enzyme engineering vaccine development and sustainable chemical production.